Clinical research progress on treatments for HER-2-positive breast cancer
10.3969/j.issn.1000-8179.2017.13.115
- VernacularTitle:抗HER-2靶向治疗乳腺癌在研临床试验进展
- Author:
Zhongsheng TONG
- Keywords:
breast cancer;
targeted therapy;
human epidermal growth factor receptor-2
- From:
Chinese Journal of Clinical Oncology
2017;44(13):630-634
- CountryChina
- Language:Chinese
-
Abstract:
For HER-2 positive breast cancer, HER-2-targeted agents combined with agents that target downstream signaling or alternative pathways, and endocrine therapy has been investigated in clinical settings. This paper focuses on studies involving phaseⅡand phaseⅢclinical trials for new targets with enhanced clinical applications, including novel small molecular targeting agents, monoclonal antibody-targeted drugs, monoclonal antibody conjugates, dual target drug combination therapy, drug targeting combined with endocrine and targeted chemotherapies, trastuzumab subcutaneous injection, and HER-2 tumor vaccine.
